ARS Pharmaceuticals, Inc. SPRY EV / sales
EV / sales at other companies
Other financials
Where this comes from
Calculated from ARS Pharmaceuticals, Inc.’s reported figures.
Based on the most recent quarter.
The official record: ARS Pharmaceuticals, Inc.’s 10-Q, filed May 15, 2026, on SEC EDGAR. View the filing →
Ask your AI about ARS Pharmaceuticals, Inc.'s ev / sales.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is ARS Pharmaceuticals, Inc.'s EV / sales?
- ARS Pharmaceuticals, Inc. (SPRY) reported EV / sales of 8.8× in Q1 2026.
- How has ARS Pharmaceuticals, Inc.'s EV / sales changed year-over-year?
- ARS Pharmaceuticals, Inc.'s EV / sales decreased by 28.6% year-over-year, from 12.3× to 8.8×.
- What is the long-term trend for ARS Pharmaceuticals, Inc.'s EV / sales?
- Over 4 years (2021 to 2025), ARS Pharmaceuticals, Inc.'s EV / sales has grown at a -39.2% compound annual growth rate (CAGR), from 104.5× to 14.3×.
- What does EV / sales mean?
- Enterprise value at the quarter end divided by trailing-twelve-month revenue. A capital-structure-neutral revenue multiple, useful when earnings are negative.